Shandong Sinoglory Health Food Co. Ltd. Class A

Shandong Sinoglory Health Food Co. Ltd. Class A

SSSE:603182
11.30
CNY
-0.10
(-0.88%)
0.53EPS
25.69P/E
2.25BMarket Cap
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
6.33
6.58
5.69
6.03
6.68
7.06
7.84
9.98
12.13
10.31
9
8.49
10.16
Basic EPS, GAAP
0.23
0.49
0.46
0.48
0.59
0.6
0.6
0.64
0.86
0.67
0.66
0.58
0.53
Free Cash Flow per Basic Share
-1.02
0.38
0.42
-0.25
- -
0.65
0.31
0.08
0.48
-0.71
-0.52
0.15
- -
Dividend per Share
0.11
0.08
0.02
0.68
0.35
0.54
0.02
0.03
0.02
0.31
0.4
0.4
0.4
Book Value per Share
1.13
1.73
2.18
2.18
1.95
2.55
3.15
3.79
5.87
6.25
6.53
6.72
6.77
Tangible Book Value per Share
0.99
1.59
1.82
1.83
1.5
2.11
2.55
3.21
5.3
5.61
5.9
6.1
6.16
Basic Weighted Avg Shares
90
110
119
122
124
123
123
124
133
164
165
163
164
Sales/Revenue/Turnover
570
723
677
737
828
870
969
1,234
1,613
1,695
1,488
1,386
1,663
Operating Margin (%)
4.9
10.07
10.49
11.94
12.14
11.43
10.73
9.1
9.74
9.2
8.84
9.07
7.33
Depreciation Expense
13
15
17
16
- -
25
26
28
34
34
33
70
- -
Net Income, GAAP
21
54
55
59
73
74
74
79
114
110
109
95
87
Effective Tax Rate (%)
25.39
25.85
25.03
24.8
23.53
22.82
24.02
22.12
22.87
25.79
23.51
24.43
24.77
Profit Margin (%)
3.63
7.45
8.08
7.96
8.83
8.5
7.65
6.41
7.09
6.5
7.33
6.83
5.24
Working Capital
-8
61
97
72
27
77
125
193
645
580
250
353
399
LT Debt
- -
- -
- -
20
24
8
24
23
- -
- -
- -
6
13
Total Equity
140
214
269
269
241
315
389
468
966
1,029
1,075
1,105
1,114
Return on Invested Capital (%)
- -
21.56
17.5
17.6
20.89
19.83
16.61
15.82
14.88
10.76
10.01
8.53
7.69
Return on Capital (%)
- -
25.63
19.05
18.14
22.36
21.18
17.28
15.72
15.29
10.97
10.13
8.57
7.77
Return on Common Equity (%)
- -
30.45
22.68
21.83
28.7
26.62
21.06
18.47
15.96
11.04
10.37
8.69
7.8

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
- -
- -
- -
LT Borrowings
10
14
13
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
165
165
165
Market Capitalization
2,672
1,876
2,253

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
585
581
552
Cash, Cash Equivalents & STI
152
139
153
Accounts Receivable, Net
102
135
135
Inventories
231
230
166
Total Current Liabilities
179
178
153
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
21%
28.11%
2.79%
Free Cash Flow
- -
9.56%
-128.71%
Net Income, GAAP
6.82%
6.7%
-13.23%
Sales/Revenue/Turnover
7.54%
8.82%
-6.89%
Total Cash Common Dividend
498.72%
309.8%
-0.61%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
394
388
325
382
1,488
2025
348
334
- -
359
1,386
2026
417
438
448
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.19
0.16
0.11
0.2
0.66
2025
0.22
0.16
- -
0.08
0.58
2026
0.17
0.18
0.11
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
0.38
0.02
- -
0.4
2025
- -
0.1
- -
- -
0.4
2026
- -
- -
0.4
- -
- -

Company Description

CEO
Guang Qing Li
Full Time Employees
857
Sector
Health technology
Industry
Pharmaceuticals: other
Address
Liaocheng China
IPO Date
Sep 11, 2023
Business
Shandong Sinoglory Health Food Co., Ltd. is an agricultural processing and biotechnology company primarily engaged in the research, development, production, and sale of soybean deep-processing products and plant-based protein ingredients. Founded in December 2000 and headquartered in Liaocheng, Shandong Province, China, the company operates across the agro-industrial and food ingredient sectors. Its comprehensive product portfolio includes soy protein isolates; soy protein concentrates; textured soy protein and textured vegetable protein granules; soy dietary fiber; edible low-temperature soybean meal and flakes; crude soybean oil; and refined soybean oil. These products serve as essential raw materials and functional additives across multiple end-market applications, including meat processing, emulsified sausages, vegetarian and plant-based meat substitutes, dairy alternatives, nutrition beverages, baked goods, snack foods, sports nutrition, and animal feed. The company operates large-scale soybean processing facilities integrating procurement, crushing, extraction, and bio-refining under a circular economy model designed for total utilization of non-GMO soybean resources. In addition to serving domestic food manufacturers, distributors, and food service providers across China, Shandong Sinoglory exports its product lines to international markets spanning approximately 100 countries and regions across Europe, North America, Asia-Pacific, the Middle East, Africa, and South America. In recent corporate developments, the company underwent a major shift in ownership and corporate control in 2026 when Shandong provincial state-owned capital acquired a controlling stake. Shandong Land Development Group Co., Ltd., backed by the State-owned Assets Supervision and Administration Commission of the Shandong Provincial People's Government (Shandong SASAC), became the controlling shareholder through a transaction valued at approximately CNY 893 million, comprising a 22.01 percent equity transfer from the founding shareholder group along with a targeted private placement to inject growth capital. Under state-owned backing, Shandong Sinoglory is expanding its core processing capacity, strengthening upstream non-GMO supply chain synergies, and broadening its research and development pipeline into high-margin health ingredients, including functional lipids, postbiotics, yeast protein, and yeast beta-glucan.